Hikma PHarmaceuticals Plc annual rePort 2013 NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 36. sHare-BaseD Payments equity-settled share option scheme During the year ended 31 December 2013, the company had one stock option compensation scheme settled by equity instruments, with four separate grant dates.
the options over these instruments are settled in equity once exercised.
Details of the grants under the scheme are shown below: The estimated fair value of each The share share option price at exercise expected number granted grant date price expected expected average contractual risk-free date of grants granted $ $ $ volatility dividend yield life interest rate 4-nov-2008 85,000 1.14 5.45 5.45 34.90% 1.21% 4.0 years 4.11% 29-apr-2008 1,041,500 2.61 9.19 9.19 31.50% 0.08% 3.8 years 4.54% 13-oct-2005 1,600,000 0.74 4.50 4.50 26.20% 6.67% 7.5 years 4.54% 12-oct-2004 9,520,000 0.35 0.91 0.91 44.80% 3.85% 7.5 years 4.22% all of the general employees share option plans have a ten-year contractual life and vesting conditions of 20% per year for five years beginning onthe first anniversary of the grant date.
the estimated fair value of each share option granted in the general employee share option plans was calculated by applying a binomial option pricing model.
it was assumed that each option tranche will be exercised immediately after the vesting date.
further details of the general employee share option plan are as follows: 2013 2012 Weighted Weighted number of averageexercise number of averageexercise shareoptions price in $ share options price in $ outstanding at 1 January 539,700 7.33 743,200 7.24 exercised during the year 302,200 7.82 179,800 6.74 expired during the year forfeitures 8,900 2.49 23,700 9.18 outstanding at 31 december 228,600 6.86 539,700 7.33 exercisable at 31 december 228,600 6.86 378,600 6.85 the cost of the equity-settled share option shows $nil 2012: $nil.
the weighted average share price at the date of exercise for share options exercised during the year was $15.9.
the options outstanding at31 December 2013 had a weighted average remaining contractual life of less than one year.
expected volatility was determined by calculating the historical volatility of the groups share price over the previous three to four years.
long-term incentive plan During the year ended 31 December 2013, the company had a long-term incentive plan ltiP settled by equity instruments, with eleven separate grant dates.
under the ltiP, conditional awards and nil cost options are granted which vest after three years, subject to a total shareholder return tsr performance condition.
this condition measures the groups tsr relative to a comparator group of other pharmaceutical companies.
in this case, the vesting schedule dictates that 20% of awards vest for median performance and 100% for upper quartile performance, with pro-rata vesting in between these points.
no awards vest for performance which is below the median.
for awards made from 2010, the tsr condition applies in respect of 50% of the award and financial metrics apply in respect of the remaining 50%.
for further details see the remuneration committee report.
the estimated fair value of each share option granted in the ltiP was calculated by applying the monte carlo simulation methodology.
for awards made from 2010, 50% of the award is subject to a tsr performance condition which was valued by applying the monte carlo simulation methodology.
the remaining 50% of the award is subject to financial metrics which are valued by applying the Black-scholes model.
the exercise price of the share award is nil.
